Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada.
Department of Medicine, Royal Inland Hospital, Kamloops, British Columbia, Canada.
Epidemiol Infect. 2021 Aug 6;149:e195. doi: 10.1017/S0950268821001874.
Our population-based study objectives were to describe characteristics and outcomes of Escherichia coli bloodstream infections (BSIs), and to evaluate factors associated with outcomes. We included incident E. coli BSIs from western interior residents (British Columbia, Canada; 04/2010-03/2020). We obtained data including patient demographics, location of onset, infection focus, Charlson comorbidity index (CCI), antimicrobial resistance, 30-day all-cause mortality and length of hospital stay (LOS). Using multivariable logistic regression models fitted with generalised estimating equations, we estimated factors associated with 30-day mortality and long post-infection LOS (>75th percentile). We identified 1080 incident E. coli BSIs in 1009 patients. The crude incidence and 30-day mortality rates were 59.1 BSIs and 6.8 deaths/100 000 person-years, respectively. The 30-day case fatality risk was 11.5%. Compared to community-acquired E. coli BSIs, either healthcare-associated or nosocomial cases had higher odds of 30-day mortality. Older cases, non-urogenital BSI foci and CCI ⩾ 3 had higher odds of 30-day mortality compared to younger cases, urogenital foci and CCI < 3. In patients that survived to discharge, those with extended-spectrum β-lactamase (ESBL)-producing E. coli BSIs, nosocomial BSIs, and CCI ⩾ 3 had higher odds of long post-infection LOS compared to those with non-ESBL-producing, community-acquired and healthcare-associated, and CCI < 3. There is a substantial disease burden from E. coli BSIs.
我们的基于人群的研究目的是描述大肠埃希菌血流感染(BSI)的特征和结局,并评估与结局相关的因素。我们纳入了来自加拿大不列颠哥伦比亚省西部内陆地区(04/2010-03/2020)的新发大肠埃希菌 BSI。我们获得的数据包括患者人口统计学特征、发病部位、感染焦点、Charlson 合并症指数(CCI)、抗菌药物耐药性、30 天全因死亡率和住院时间(LOS)。使用广义估计方程拟合的多变量逻辑回归模型,我们估计了与 30 天死亡率和感染后 LOS 延长(>第 75 百分位数)相关的因素。我们确定了 1009 例患者中的 1080 例大肠埃希菌 BSI。粗发病率和 30 天死亡率分别为 59.1 例/100000 人年和 6.8 例/100000 人年。30 天病死率为 11.5%。与社区获得性大肠埃希菌 BSI 相比,医院获得性或医院内的病例 30 天死亡率更高。与年轻病例、泌尿生殖系统焦点和 CCI<3 相比,老年病例、非泌尿生殖系统焦点和 CCI ⩾3 的病例 30 天死亡率更高。在存活至出院的患者中,与非产 ESBL 大肠埃希菌 BSI、医院获得性 BSI 和 CCI ⩾3 的患者相比,产 ESBL 大肠埃希菌 BSI、社区获得性和医院获得性 BSI 和 CCI<3 的患者具有更高的感染后 LOS 延长的可能性。大肠埃希菌 BSI 有很大的疾病负担。